Vanguard Group Inc Eiger Bio Pharmaceuticals, Inc. Transaction History

Vanguard Group Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.21 - $0.43 $30,142 - $61,720	-143,535 Reduced 7.31%	1,820,767 $400,000
Q2 2023 Aug 14, 2023	SELL	$0.55 - $1.26 $112,256 - $257,168	-204,102 Reduced 9.41%	1,964,302 $1.38 Million
Q1 2023 May 15, 2023	BUY	$0.89 - $2.52 $94,146 - $266,573	105,783 Added 5.13%	2,168,404 $1.95 Million
Q4 2022 Feb 10, 2023	BUY	$1.02 - $7.48 $32,678 - $239,644	32,038 Added 1.58%	2,062,621 $2.43 Million
Q3 2022 Nov 14, 2022	BUY	$6.04 - $9.66 $671,931 - $1.07 Million	111,247 Added 5.8%	2,030,583 $15.3 Million

Q2 2022 Aug 12, 2022	BUY	$4.99 - $8.96 $1.15 Million - $2.06 Million	230,093 Added 13.62%	1,919,336 $12.1 Million
Q1 2022 May 13, 2022	SELL	$3.84 - $9.74 $31,787 - $80,627	-8,278 Reduced 0.49%	1,689,243 $14 Million
Q4 2021 Feb 14, 2022	BUY	$5.12 - $8.19 $5,099 - $8,157	996 Added 0.06%	1,697,521 $8.81 Million
Q3 2021 Nov 12, 2021	BUY	$6.68 - $9.1 $76,131 - $103,712	11,397 Added 0.68%	1,696,525 $11.3 Million
Q2 2021 Aug 13, 2021	BUY	$7.82 - $9.23 $13.2 Million - $15.6 Million	1,685,128 New	1,685,128 $14.4 Million

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $556M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.